何氏眼科12月5日公告，公司董事长、总经理何伟因公司治理及业务发展需要，申请辞去公司总经理职 务，辞职后将不再担任公司总经理职务，但仍继续担任公司董事长等职务。公司董事会同意聘任何星儒 担任公司总经理，任期自本次董事会审议通过之日起至第三届董事会届满之日止。 ...

目前，以上各项获奖专利已陆续进入后续研发试验与临床应用阶段，并获得国内多家知名医疗科技企业 的合作与融资支持，并进入实质性架构模型的研发转化应用阶段。 据了解，近年来，光正眼科积极深化产学研医协同创新，先后携手同济大学附属同济医院、复旦大学附 属眼耳鼻喉科医院、江南大学等国内顶尖机构，共同成立"上海新视界眼科中心""眼健康创新技术联合 实验室""江南大学新视界眼科研究中心"三大创新平台，组建起跨学科、跨领域的创新技术研发团队。 团队以前沿技术为突破口，重点布局AI眼科智能诊断系统、微创诊疗器械研发等战略领域。此次取得 的青光眼诊疗专利技术突破，正是其创新研发体系结出的硕果，充分彰显了光正眼科以创新驱动为核 心、引领眼科医疗技术迭代升级的坚定决心。 光正眼科相关负责人对此表示，接下来，光正眼科将以此次获奖为契机，继续深耕"AI+医疗"领域，深 化与高校及科研机构的产学研合作，加大在AI诊疗、基因治疗等前沿领域的研发投入，推动眼科医疗 与人工智能、大数据等前沿技术深度融合；同时，依托自身医疗服务网络，让创新成果更快惠及广大眼 病患者。（秦声） 近日，在第八届（2025）中国医疗器械创新创业大赛全国总决赛中，由同济 ...

格隆汇12月4日丨朝聚眼科(02219.HK)公告，12月4日耗资32万港元回购12万股，回购价格每股2.63-2.7 港元。 ...

Core Viewpoint - The company, 朝聚眼科 (stock code: 02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares [1] - The total expenditure for the buyback is HKD 319,200 [1] - The buyback price per share ranges from HKD 2.63 to HKD 2.70 [1]

朝聚眼科(02219)发布公告，于2025年12月4日，该公司斥资31.92万港元回购12万股股份，每股回购价格 为2.63-2.7港元。 ...

21世纪经济报道记者 杨坪 近日，21 世纪经济报道记者获悉，深交所组织上市公司赴德国举办"投资中国新机遇"—深市上市公司 法兰克福路演交流会。 活动旨在向当地投资者宣介"十五五"时期中国经济高质量发展前景，面对面讲好深市上市公司科技发展 故事，推动当地投资者更好理解中国资本市场发展机遇与投资价值，进一步助力服务中德产业投资合 作。 据悉，今年以来，深交所在香港、新加坡、韩国、澳大利亚、德国等地和境内累计组织已开展11场境外 路演及境外投资者走进上市公司活动，覆盖超50家次深市上市公司，向境外机构投资者多维度展示深市 上市公司投资价值和中国经济高质量发展新机遇。 多家与会的投资机构表示，通过一系列的路演活动，深入了解了企业的经营情况和发展前景，切身感受 到中国企业在全球化、数字化、高端化、绿色化的微观活力，成为重塑全球价值链的重要力量，将持续 关注中国市场的投资机会，对中国资产的长期投资价值充满信心。 据了解，此次参与法兰克福路演交流会的深市上市公司分别为阳光电源、潍柴动力、爱尔眼科、罗博特 科、海亮股份，来自数字经济、高端制造、绿色低碳等新质生产力领域，并在德国或欧洲有本地化业 务。 与会投资者评价中德两国 ...

Group 1 - The Shenzhen Stock Exchange announced a periodic adjustment of sample stocks for various indices, including the Shenzhen Component Index and the ChiNext Index, effective December 15, 2025 [1] - Huaxia Eye Hospital (301267) is one of the stocks being removed from the ChiNext Index sample list [1] Group 2 - Huaxia Eye Hospital was listed on the ChiNext on November 7, 2022, with an initial offering price of 50.88 RMB per share and is currently in a state of decline [2] - The total funds raised from the initial public offering amounted to 305.28 million RMB, with a net amount of 276.85 million RMB after deducting issuance costs [2] - The company originally planned to raise 77.85 million RMB for various projects, including hospital construction and operational upgrades, but ultimately raised 198.99 million RMB more than planned [2] Group 3 - In the 2022 annual shareholders' meeting held on May 15, 2023, the company approved a profit distribution plan, distributing a cash dividend of 2.8 RMB per 10 shares, totaling 15.68 million RMB [3] - The company also approved a capital reserve increase, converting 5 shares for every 10 shares held, increasing the total share capital from 56 million shares to 84 million shares [3] - Huaxia Eye Hospital Group was established in 2004 in Xiamen, Fujian Province, with a registered capital of 84 million RMB [3]

Bausch + Lomb (NYSE:BLCO) FY 2025 Conference December 03, 2025 09:00 AM ET Company ParticipantsBrent Saunders - CEOSam Eldessouky - CFOConference Call ParticipantsNone - AnalystNoneHello, and good morning, everybody, to day two of the Citibank Global Healthcare conference here in Miami. And I am Joanne Lynch, the medical technology analyst here. And I'm thrilled that we're going to start this session with the management of Bausch + Lomb. Brent Saunders is Chairman and CEO, and Sam, oh, I'm going to call you ...

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [5][6][11] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% [13][15] - The company aims for a net leverage of 3.5 times by 2028 [18] Business Line Data and Key Metrics Changes - The Vision 27 program is designed to enhance operational efficiency and gross margins across various business lines [6][11] - The contact lens segment is expected to grow faster than the market, with a new bioactive platform, Project Halo, set to launch in 2028 [21][27] - The dry eye product portfolio, including Xiidra and Miebo, is positioned as the gold standard in the market [52] Market Data and Key Metrics Changes - The contact lens market has slowed to about 4% growth, influenced by economic conditions in Asia, particularly China [28][29] - The company anticipates a recovery in the contact lens market, projecting growth to return to 5% or higher by 2026 [29] Company Strategy and Development Direction - The company is committed to organic growth, with no M&A planned in the three-year strategy [18] - Focus on innovation is critical, with a deep pipeline of products expected to drive future growth [90] - The company aims to leverage its existing infrastructure for new product launches to maintain high margins [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation into a high-performance competitor, emphasizing the importance of innovation and operational excellence [5][6] - The management highlighted the need for a disciplined approach to spending as growth resumes [9][11] - The company is optimistic about the aging population's demand for premium IOLs, viewing it as a growth driver [89] Other Important Information - The company is focusing on enhancing its R&D efficiency, aiming to allocate more resources towards product development rather than administrative costs [50] - The introduction of new products like Lumify Luxe and the expansion of the PreserVision brand are seen as significant growth opportunities [44][46] Q&A Session Summary Question: How should investors think about the liquidity of Bausch + Lomb given its ownership structure? - Management acknowledged the 88% ownership by Bausch Health and indicated that both boards are committed to addressing liquidity issues, though the timeline is uncertain [12] Question: What are the components of the 5%-7% revenue long-range plan? - Management explained that the guidance is based on current market conditions and internal capabilities, with a balanced approach to growth [13][15] Question: How does the company view tuck-in M&A opportunities? - Management stated that no M&A is needed at this time, focusing instead on organic growth and improving the balance sheet [18] Question: What is the expected timeline for the new bioactive contact lens material? - The new product is expected to launch in 2028, with ongoing clinical studies providing positive data [24][27] Question: How does the company plan to manage its R&D budget? - The company is increasing its R&D spending to about 7.5% of revenue, focusing on high-potential programs [48][50] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for dry eye treatment, with Xiidra and Miebo positioned as leading products [52] Question: What is the growth outlook for the surgical business? - The surgical business is expected to grow steadily, driven by an aging population and consistent demand for IOLs [89]

（文章来源：证券日报） 证券日报网讯 12月3日，爱尔眼科在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东 总数为344788户。 ...